AbbVie will reportedly give up global patent rights for its HIV drug Kaletra, which is being evaluated in several clinical trials as treatment for severe COVID-19, to address rising demand for experimental coronavirus drugs. The move will allow countries to buy Kaletra generics if the drug is found to be an effective COVID-19 treatment or if a shortage occurs.
AbbVie reportedly drops global patent rights for HIV drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.